DavidPrestonHollandMD

PubMed

• 9 citations
  Time to Sputum Culture Conversion and Treatment Outcomes Among Patients with Isoniazid-Resistant Tuberculosis in Atlanta, Georgia.
  Marcos C. Schechter, Destani J. Bizune, Michelle Kagei, Mamuka Machaidze, David P. Holland
  Clinical Infectious Diseases. 2017-11-13
• 66 citations
  Intracranial tuberculomas developing while on therapy for pulmonary tuberculosis.
  Deborah Nicolls, Mark King, David P. Holland, Jennifer Bala, Carlos del Rio
  The Lancet. Infectious Diseases. 2005-12-01
• 23 citations
  COVID-19 Infection Prevention and Control Adherence in Long-Term Care Facilities, Atlanta, Georgia.
  Carson T Telford, Cyndra Bystrom, Teresa Fox, David P. Holland, Sherry Wiggins-Benn
  Journal of the American Geriatrics Society. 2021-03-01

Journal Articles

• Three Months of Weekly Rifapentine plus Isoniazid Is Less Hepatotoxic than Nine Months of Daily Isoniazid for LTBI  
  Bliven-Sizemore EE, Sterling TR, Shang N, Benator D, Schwartzman K, Reves R, Drobeniuc J, Bock N, Villarino ME; TB Trials Consortium, Int J Tuberc Lung Dis, 1/1/2015
• Treatment for Preventing Tuberculosis in Children and Adolescents: A Randomized Clinical Trial of a 3-month, 12-dose Regimen of a Combination of Rifapentine and Isoniazid  
  Villarino ME, Scott NA, Weis SE, Weiner M, Conde MB, Jones B, Nachman S, Oliveira R, Moro RN, Shang N, Goldberg SV, Sterling TR; International Maternal Pediatric and A..., JAMA Pediatr, 1/1/2015
• Translating Tuberculosis Research into Practice: Collaboration between Academic Researchers and Public Health Departments in North Carolina  
  Holland DP, Hecker EJ, Mosher AW, Stout JE, NC Med J, 1/1/2013
• Cost-effectiveness of a 12-dose Regimen for Treating Latent Tuberculous Infection in the United States  
  Shepardson D., Marks SM, Chesson H, Kerrigan A, Holland DP, Scott N, Tian X, Borisov, AS, Shang N, Heilig CM, Sterling TR, Villarino ME, MacKenzie WR, Int J Tuberc Lung Dis, 1/1/2013
• Public health costs for tuberculosis suspects in Wake County, North Carolina, United States  
  Park PH, Holland DP, Wade A, Goswami ND, Bissette D, Stout JE, Int J Tuberc Lung Dis, 1/1/2013
• Current Management Options for Latent Tuberculosis: A Review  
  Norton BE, Holland DP, Infect Drug Resist, 1/1/2012
• Effect of HIV Infection on Tolerability and Bacteriologic Outcomes of Tuberculosis Treatment  
  Bliven-Sizemore EE, Johnson JL, Goldberg S, Burman WJ, Villarino ME, Chaisson RE; Tuberculosis Clinical Trials Consortium, Int J Tuberc Lung Dis, 1/1/2012
• Strategies for Treating Latent Multiple-drug Resistant Tuberculosis: A Decision Analysis  
  Holland DP, Sanders GD, Hamilton CD, and Stout JE, PLoS One, 1/1/2012
• Potential Economic Viability of Two Proposed Rifapentine-based Regimens for Treatment of Latent Tuberculosis Infection  
  Holland DP, Sanders GD, Hamilton CD, and Stout JE, PLoS One., 1/1/2011
• Three Months of Rifapentine and Isoniazid for Latent Tuberculosis Infection  
  Sterling TR, Villarino ME, Borisov AS, Shang N, Gordin F, Bliven-Sizemore E, Hackman J, Hamilton CD, Menzies D, Kerrigan A, Weis SE, Weiner M, Wing D, Conde MB, Bozema..., N Engl J Med, 1/1/2011
• Did the “Great Recession” Produce a Depression in Tuberculosis Incidence?  
  Holland DP, Person AK, Stout JE, Int J Tuberc Lung Dis, 1/1/2011
• Effect of Improving the Quality of Radiographic Interpretation on the Ability to Predict Pulmonary Tuberculosis Relapse  
  Stout JE, Kosinski AS, Hamilton CD, Goodman PC, Mosher A, Menzies D, Schluger N, Khan A, Johnson JL; on behalf of the Tuberculosis Trials Consortium, Acad Radiol, 1/1/2010
• Substitution of Moxifloxacin for Isoniazid during Intensive Phase Treatment of Pulmonary Tuberculosis  
  Dorman SE, Johnson JL, Goldberg S, Muzanye G, Padayatchi N, Bozeman L, Heilig CM, Bernardo J, Choudhri S, Grosset JH, Guy E, Guyadeen P, Leus MC, Maltas G, Menzies D, ..., Am J Respir Crit Care Med, 1/1/2009
• Therapeutic Drug Monitoring of Anti-mycobacterial Medications in Patients with Tuberculosis and Advanced Human Immunodeficiency Virus Infection  
  Holland DP, Hamilton CD, Weintrob AC, Engemann JJ, Fortenberry ER, Peloquin CA, and Stout JE, Pharmacotherapy, 1/1/2009
• Quality Assurance in a Large Clinical Trials Consortium: The Experience of the Tuberculosis Trials Consortium  
  Sandman L, Mosher A, Khan A, Tapy J, Condos R, Ferrell S, Vernon A; on behalf of the Tuberculosis Trials Consortium, Contemp Clin Trials, 1/1/2006
• Intracranial Tuberculomas Developing while on Therapy for Pulmonary Tuberculosis  
  Nicolls DJ, Bala J, King M, Holland D, del Rio C, Lancet Infect Dis., 1/1/2005
• Influence of M Tuberculosis Lineage Variability within a Clinical Trial for Pulmonary Tuberculosis  
  Nahid P, Bliven EE, Kim EY, Mac Kenzie WR, Stout JE, Diem L, Johnson JL, Gagneux S, Hopewell PC, Kato-Maeda M; on behalf of the Tuberculosis Trials Consortium, PLoS One., 1/20/2010
• Costs and Cost Effectiveness of Four Treatment Regimens for Latent Tuberculosis Infection  
  Holland DP, Sanders GD, Hamilton CD, and Stout JE, Am J Respir Crit Care Med, 1/1./2009
• Moxifloxacin versus Ethambutol in the First 2 Months of Treatment for Pulmonary Tuberculosis  
  Burman WJ, Goldberg S, Johnson JL, Muzanye G, Engle M, Mosher AW, Choudhri S, Daley CL, Munsiff SS, Zhao Z, Vernon A, Chaisson RE, on behalf of the Tuberculosis Trials..., Am J Respir Crit Care Med, 1/1./2006
• Join now to see all

Abstracts/Posters

• Mycobacteriology Diagnostic Costs in an Inner-City Public Hospital: Are We Ready to Adopt the Xpert(R) MTB/RIF in Lieu of the Acid-Fast Bacilli (AFB) Smear?
  Schechter MC,* Snoeyenbos G, Wang YF, Holland DP, and Ray SR, ID Week, San Diego, CA, 1/1/2015
• Does the Use of Key Terjms in Radiologic Interpretation Influence Treatment Initiation?
  Zeringue EN,* Allen MG, Luffman J, Fortenberry E Herrin KB, Stout JE, Holland DP, National TB Controllers Association, Atlanta, GA, 1/1/2014
• 3HP in the Real World – The North Carolina Experience
  Zeringue EN,* Allen MG, Luffman J, Fortenberry E Herrin KB, Stout JE, Holland DP, National TB Controllers Association, Atlanta, GA, 1/1/2014
• Strategies for Treating Latent Multiple-drug Resistant Tuberculosis
  Holland DP,* Sanders GD, Hamilton CD, Stout JE, Modeling for Public Health Action, Atlanta, GA, 1/1/2010
• Therapeutic Drug Monitoring in Patients with Tuberculosis and Advanced Human Immunodeficiency Virus Infection
  Holland DP,* Stout JE, Weintrob AC, Engemann JJ, Fortenberry ER, Peloquin CA, Hamilton CD, American Thoracic Society, Toronto, ON, 1/1/2008
• Communicating with Legislators: Amending Georgia Public Health Laws on Confinement of Non-Adherent Tuberculosis Patients
  Sales R,* DeVoe-Payton B, Leonard M, Holland D, Buford K, Keating S, National TB Controllers’ Association, Atlanta, GA, 1/1/2005
• Tuberculosis Epidemiology in Atlanta Georgia -- A Comparison of STD Program Contact Elicitation Strategies to Traditional Tuberculosis Case Management and Contact Inve...
  Hardy RL,* Hartwell V, Chastang D, Brown R, Johnson D, Holland DP, Sturdivant R, Lilly M, Taylor C., National TB Controllers’ Association, Washington, DC, 1/1/2003
• Join now to see all

Lectures

• Appropriate Drug Regimens for MDR-TB Patients and Contacts 
  North Carolina Tuberculosis/Respiratory Diseases Institute - 1/1/2015
• Using Imperfect Tests for the Diagnosis of LTBI 
  Atlanta, GA - 1/1/2014
• Evaluating New LTBI Regimens 
  Atlanta, GA - 1/1/2014
• Choosing an LTBI Regimen 
  North Carolina Tuberculosis/Respiratory Diseases Institute - 1/1/2014
• HIV – Stigma vs. Facts 
  1/1/2014
• Treating Tuberculosis: Two Steps Forward, One Step Back 
  Emory University, Atlanta, GA - 1/1/2014
• Treatment of Tuberculosis: Two Steps Forward, One Step Back 
  Duke University, Durham, NC - 1/1/2013
• Cost-effectiveness of LTBI Treatment 
  Atlanta, GA - 1/1/2013
• TB in Correctional Facilities 
  1/1/2013
• Cost Effectiveness of LTBI Therapy 
  Savannah, GA - 1/1/2013
• Bayesian Reanalysis of TBTC Study 28 
  Atlanta, GA - 1/1/2013
• Update on Treatment of Latent TB Infection 
  Chicago, IL - 1/1/2013
• Primum Non Nocere - Difficult Case Presentation 
  1/1/2012
• Guidelines for Short-course Treatment of LTBI 
  1/1/2012
• Beyond the ‘ABCs:’ HIV Prevention in 2012 
  Duke University, Durham, NC - 1/1/2012
• Tuberculosis 
  Duke Global Health Institute, Duke University, Durham, NC - 1/1/2012
• Rifamycins for the Treatment of Latent Tuberculosis Infection 
  North Carolina Tuberculosis/Respiratory Diseases Institute - 1/1/2011
• Translating Research into Practice: The North Carolina Experience 
  1/1/2011
• Economic Considerations of Short-Course Therapy for LTBI 
  Richmond, VA - 1/1/2011
• Keynote Address: “Treating Latent TB Infection - An Update” 
  Charleston, WV - 1/1/2011
• North Carolina IGRA Guidelines 
  1/1/2010
• Latent TB Infection and the Science behind the IGRA Guidelines 
  Vancouver, BC - 1/1/2010
• CDC Guidelines for using Interferon-gamma Release Assays to Detect TB Infection 
  Raleigh, NC - 1/1/2010
• Treating Latent MDR-TB Infection: Picking Your Poison 
  Duke University, Durham, NC - 1/1/2010
• Decision Analysis in the Planning of Clinical Trials: Treatment of Latent MDR-TB Infection 
  Duke University, Durham, NC - 1/1/2010
• Join now to see all

Other

• Getting PrePared: Questions and Answers about a New Method of HIV Prevention 
  Holland DP, The Triangle: LGBTQ resource for the Raleigh, Durham and Chapel Hill area
  1/1/2012
• North Carolina Guidelines for the Use of Interferon Gamma Release Assays (IGRAS) in Tuberculosis Diagnosis 
  Stout JE, Hendershot E, Holland DP, Ahmed A, Allen M, Fortenberry ER, Luffman J, Zeringue E, Herrin K, O’Rourke M, Ewing A, Ohl C, Cook P, Frothingham R, Hamilton CD, ..., NC Tuberculosis Control Website
  1/1/2009
• Nucleic Acid Amplification Testing (NAA) For Tuberculosis: North Carolina State Laboratory of Public Health Testing and General Guidelines for Interpretation 
  Holland DP, NC Tuberculosis Control Manual